Avidity Biosciences, Inc. provided an update on the Phase 1/2 MARINA™ trial of AOC 1001 in adults with myotonic dystrophy type 1 , an underrecognized, progressive and often fatal neuromuscular. | March 31, 2023
Item 7.01. Regulation FD Disclosure.
On March 30, 2023, Avidity Biosciences, Inc. will
hold a webcast and conference call focused on a regulatory update to the
Company s Phase 1/2 MARINA™. | March 30, 2023
SAN DIEGO, Jan. 20, 2023 /PRNewswire/ Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ,. | January 20, 2023
By Colin Kellaher Avidity Biosciences Inc. on Wednesday said the U.S. Food and Drug Administration granted fast-track designation to its AOC 1020 for the treatment of facioscapulohumeral. | January 18, 2023
San Diego-based biopharmaceuticals company Avidity Biosciences said on Thursday that it has upsized its public offering, and will be offering up 12,000,000 shares of its common stock at a price to the p